Navigation Links
Amira Pharmaceuticals to Present at Montgomery Healthcare Conference
Date:10/6/2009

SAN DIEGO, Oct. 6 /PRNewswire/ -- Amira Pharmaceuticals, Inc., a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease, announced today that Robert Baltera, Chief Executive Officer, will present a company overview at the Montgomery Healthcare Conference 2009 in Menlo Park, Calif., today.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease. Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions. Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®. The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future. For more information, visit www.amirapharm.com.

SOURCE Amira Pharmaceuticals, Inc.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Amira Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference
2. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM211, a Novel Product Candidate for the Treatment of Respiratory Diseases
3. Amira Pharmaceuticals to Present Preclinical Data from LPA1 Receptor Antagonist Program at FASEB Summer Research Conference
4. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
5. Amira Announces the Successful Completion of GLP Toxicity Studies for a Novel DP2 Antagonist.
6. Amira Pharmaceuticals Achieves Milestones in FLAP Inhibitor Program With GlaxoSmithKline
7. Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors
8. Amira Pharmaceuticals and GlaxoSmithKline Enter Global Agreement for FLAP Inhibitor Program
9. Amira Pharmaceuticals Appoints First Vice President of Development
10. Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease
11. Cadence Pharmaceuticals CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... ... 21, 2017 , ... Hanna Boys Center http://www.hannacenter.org ... the keynote speaker at its second Professional Networking Breakfast on March 9, 2017. ... comprehensive strategies to create and expand opportunities for boys and young men of ...
(Date:2/21/2017)... ... February 21, 2017 , ... As recently as 2015, rhinoplasty was one of ... of Plastic Surgeons. Some patients want to make a change in the appearance of ... their breathing ability. The team at usrhinoplasty.org is expanding its article database ...
(Date:2/21/2017)... (PRWEB) , ... February 21, 2017 , ... Ray Insurance ... communities in and around Tarrant County, is embarking on a six month charity event ... and treatments for cancer. , Cancer is one of the deadliest diseases in America; ...
(Date:2/21/2017)... ... February 21, 2017 , ... American Veterinarian™, the premier multimedia ... launching its first bi-monthly issue of 2017 in February. The inaugural issue will ... One Health. , In making the announcement, American Veterinarian™ Publisher Chris Hennessy ...
(Date:2/21/2017)... ... 2017 , ... Each February the nation reflects upon African ... American History Month ). This month-long celebration encourages reflection upon the ... people, but also the opportunity to examine the trends of addiction among African ...
Breaking Medicine News(10 mins):
(Date:2/21/2017)... 21, 2017 Cadence Design Systems, Inc. (NASDAQ: ... Tensilica ® Fusion F1 DSP is part of the ... The licensable IP targets SoCs designed for battery-powered sensor nodes ... leveraged the Fusion F1 DSP both to implement the IEEE ... trigger, audio identification and sensor fusion on a single DSP. ...
(Date:2/21/2017)... and Markets has announced the addition of the "Rosacea Drugs Price ... ... Analysis and Strategies - 2016, provides drug pricing data and benchmarks in ... What are the key drugs marketed for Rosacea ... market? What are the unit prices and annual treatment ...
(Date:2/20/2017)... , Feb. 21, 2017 Taiwan Biophotonic ... provider of non-invasive vital signs sensing solutions, today announced ... first finger-free wrist pulse oximeter, the oCare TM Pro ... wearable healthcare and medical devices space.  tBPC,s ... provides a non-invasive, simple and reliable method to measure ...
Breaking Medicine Technology: